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synechael angle closure glaucoma, often resulting in 
loss of vision.[2,3] New blood vessel formation on the 
iris is triggered by vascular endothelial growth factors 
diff using anteriorly from a hypoxic retina.[4,5] It has 
been suggested that iris neovascularization is never 
primary but secondary to other ocular disorders.[6] 
Hypoxic retinae may result from diabetic retinopathy, 
central retina vein occlusion (CRVO), branch retina 
vein occlusion (BRVO), central retina artery occlusion 
(CRAO), uveitis, longstanding retinal detachment, 
intraocular tumors, carotid obstructive disease and 
carotico-cavernous fi stulae, all of which may lead to 
NVG.[2,6]
In Ibadan, Nigeria, NVG constituted 0.4% of new 
patients a  ending an eye clinic with retinal vein 
occlusion (RVO) being the etiological factor in the 
INTRODUCTION
Neo-vascular glaucoma (NVG) is a secondary glaucoma 
occurring with the formation of a fi brovascular 
membrane on the anterior surface of the iris (rubeosis 
iridis) which extends to the anterior chamber angle.[1]
An initial open angle glaucoma then progresses to angle 
closure as the fi brovascular tissue contracts to produce 
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ABSTRACT
Objective: To determine the causes and the intraocular pressure (IOP) outcome of neo-vascular glaucoma at the Guinness 
Eye Centre of the Lagos University Teaching Hospital, Lagos, Nigeria. Materials and Methods: The case records of all patients 
with the diagnosis of neo-vascular glaucoma who presented at Guinness Eye Centre from January 1st, 2008 to December 
31st, 2012 were reviewed. Information extracted from their records included the bio-data, eye affected, best corrected visual 
acuity, intra-ocular pressure, etiology of neo-vascular glaucoma, ocular co-morbidity, systemic co-morbidity and forms of 
treatment received. Cases of retinoblastoma were excluded from the study. Data were analyzed using the SPSS V.17.1 
Results: A total of 31 cases of neovsacular glaucoma were reviewed. The male to female ratio was 1.8:1 and the age range 
was from 26 to 83 years. Patients aged 51 years or older were 22 (70.4%). The presenting best corrected visual acuity in the 
affected eye or in the worse affected eye was counting fi ngers in 30 (96%) patients. The presenting IOP was 30 mmHg or 
higher in 26 (83.2%). Both eyes were affected in three (9.6%) patients. Patients with diabetes mellitus, hypertension or both 
constituted 57.8% of the total number of patients. Primary open angle glaucoma and retina vein occlusion were the etiologies 
of neo-vascular glaucoma in 14 (45.2%) patients. A total of 15 (48.4) patients failed to turn up for repeat appointments. Only 
5 (16.0%) patients (who received ocular medications, intravitreal bevacizumab and pan-retina photocoagulation) showed a 
signifi cant IOP reduction. Conclusion: Late presentation, loss to follow up and lack of full and complete treatment regime 
were important fi ndings in this study. A signifi cant IOP reduction occurred with only in the patients who had a combination 
therapy of IOP lowering medications, intravitreal bevacizumab and pan-retina photocoagulation. A routine eye examination 
for patients at risk is essential for early detection and treatment in order to minimize visual loss in neo-vascular glaucoma.
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presentation was 58.9 years and the age range was from 
26 to 83 years. Patients aged 51 years and above were 
22 (70.4%) as shown in Figure 1.
The right eye alone was involved in 15 (48.0%) patients 
and the left eye alone in 13 (41.6%). Both eyes were 
involved in NVG in 3 (9.6%) patients. The presenting 
best corrected visual acuity (BCVA) in the aff ected eye, 
or in the be  er eye where both eyes were aff ected, was 
counting fi ngers (CF) or worse in 30 (96%) patients. 
This is shown in Table 1.
In the non-aff ected eye, 6 (19.4%) patients had visual 
acuity of 3/60 or worse. Twelve patients (38.7%) had no 
associated systemic disorders, while 10 patients (32%) 
and 1 patient (3.2%), respectively, had hypertension 
and diabetes mellitus (DM) only. However, seven 
(22.6%) patients had both hypertension and DM 
concurrently [Table 2].
majority (78.7%) of subjects.[7] A study in Cameroon 
showed that NVG constituted 47.7% of all secondary 
glaucomas.[8] The most common causes of NVG in 
Romania are diabetic retinopathy, ischemic CRVO 
and ocular ischemic syndromes.[9] NVG accounted 
for 16 (22%) of all secondary glaucomas seen in a 
tertiary eye centre in Paraguay.[10] In Thailand, the 
most common causes of NVG were CRVO (47%), 
proliferative diabetic retinopathy (42%), and ocular 
ischemic syndromes (5%).[11] In Saudi Arabia, the 
common causes of neovascular glaucoma were diabetic 
retinopathy (56.0%), retina venous obstruction 26.4% 
and chronic retinal detachment (3.56%).[12]
The treatment of NVG may be pharmacological or 
surgical such as trabeculectomy, aqueous drainage 
implants, cryotherapy or laser partial destruction of the 
ciliary body, photocoagulation of the hypoxic retina or 
a combination of any of these. The use of anti vascular 
endothelial growth factors is a signifi cant milestone in 
the management of NVG as they block the formation of 
new blood vessels in the eye. Bevacizumab, for example 
binds to the VEGF-A, thereby inhibiting angiogenesis.[13]
The methods of treatment employed in a particular case 
can be individualized based on the available options, 
severity of disease and potential for vision.
This study aims to determine the common causes and 
outcome of treatment of NVG in patients a  ending the 
retina clinic of the Lagos University Teaching Hospital.
MATERIALS AND METHODS
This is a retrospective study of the causes of and the 
outcome of treatment for NVG at the Guinness Eye Centre, 
Lagos University Teaching Hospital, Lagos, Nigeria. 
Ethical approval was obtained from the Lagos University 
Teaching Hospital Research and Ethics Commi  ee. All 
new cases a  ending the eye clinic from January 2008 to 
December 2012 with the diagnosis of ‘NVG’ had their 
records retrieved manually by the medical records offi  cers. 
Information extracted from the records included bio-data, 
eye aff ected, best corrected visual acuity, intraocular 
pressure (IOP), etiology of NVG, ocular co-morbidity, 
systemic co-morbidity, and forms of treatment received. 
All cases of retinoblastoma were excluded as they are not 
normally labeled as cases of NVG in our centre. Data were 
analyzed using the SPSS V.17. 1
RESULTS
A total of 31 patients had NVG out of the total number 
of 52,335 new patients seen at the Guinness Eye 
Centre during the period of review. This gives a clinic 
incidence of 0.06%. There were 20 males and 11 females 


























Figure 1: Age groups
Table 1: The BCVA at presentation in the affected 
(or worse affected) eye
BCVA Frequency Percent
6/24-6/36 1 3.2
Counting fingers 2 6.5
Hand movement/perception of light 8 25.8
No perception of light 20 64.5
Total 31 100.0
BCVA: Best corrected visual acuity
Table 2: Associated systemic disorders
Associated systemic disorders Frequency Percent
Hypertension alone 10 32.0
Diabetes mellitus alone 1 3.2
Hypertension and diabetes mellitus 7 22.6
Sickle cell disease 1 3.2
No known systemic association 12 38.7
Total 31 100
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Three (9.3%) patients had associated ocular trauma 
(couching). Ten (32%) patients had retinal vascular 
occlusion either without a known etiology or secondary 
to glaucoma or diabetic retinopathy [Table 3].
Ocular medications alone (atropine, steroid eye drops 
and anti-glaucoma tablets and drops) represented the 
form of treatment most solely utilized by majority of 
the patients. Twenty-four (76.8%) patients took up 
this form of treatment alone, whereas, only 5 (16.0%) 
patients had a combination therapy consisting 
of ocular medications, intravitreal bevacizumab 
injections and pan-retina photocoagulation as shown 
in Table 4.
The IOP at presentation was 30 mmHg or higher in 
26 (83.2%) patients. In all, 15 (48.4%) patients failed to 
turn up for follow-up appointments after the fi rst visit. 
The remaining patients who turned up for appointments 
had varying IOP reductions depending on treatments 
received. Five (16%) patients who had a combination 
therapy of ocular medications, intraocular bevacizumab 
injections and retinal laser photocoagulation treatments 
showed an average IOP reduction of 19 mmHg [Table 5]. 
However, the remaining 11 patients who came for 
follow-up but did not receive either intravitreal 
bevacizumab or PRP showed diff erent pa  ern of IOP 
outcomes. While 3 eyes had a further elevation of IOP, 
one eye became phthisical [Table 6].
DISCUSSION
With a male to female ratio of 1.8:1, male patients in this 
study were almost twice as many as females. This may 
be a refl ection of unequal access to eye care services 
rather than male susceptibility to NVG.
The mean age at presentation of 58.9 years is comparable 
to the mean age at presentation in the Ibadan study.[7]
Twenty-two (70.4%) patients were aged 51 years and 
above with the age range 61–70 years having the 
highest frequency [Figure 1]. This is to be expected as 
the diseases likely to cause NVG such as glaucoma, 
DM, and hypertension become more chronic with 
advancing age.
The BCVA at presentation was very poor. Thirty (96.8%) 
patients presented with BCVA of counting fi ngers or 
worse in the aff ected eye (or in the be  er eye where both 
eyes were involved) suggesting that patients in this 
study generally presented late. This is underscored by 
the fi nding that no patients showed any improvement 
in vision and two of them actually deteriorated from 
BCVA of hand movement/perception of light to no 
perception of light.










4 19 14 −5
13 35 54 +19
14 15 48 +33
17 Not available Not available 0
18 16 12 −2
26 42 34 −8
27 40 34 −6
28 Not available 15 0
29 52 52 0
30 46 0 −46
31 22 40 +22
−: Means IOP reduction, +: Means IOP increase, IOP: Intraocular pressure
Table 4: Forms of treatment uptake
Treatment modality Frequency Percent
Ocular medications alone 24 76.8
Ocular medications, bevazucimab and PRP 5 16.0
Ocular medications and bevazucimab alone 2 6.4
Total 31 100.0
PRP: Pan retinal photocoagulation
Table 5: IOP readings in patients who came 










5 19 10 10
12 30 18 12
15 43 18 25
23 38 29 9
24 52 15 37
Average 36.4 18 19
PRP: Pan retinal photocoagulation, IOP: Intraocular pressure
Table 3: Neo vascular glaucoma and associated 
ocular disorders
Associated ocular disorders Frequency Percent
Primary open angle glaucoma 7 22.6
Nil association 6 19.4
CRVO 4 12.9





Retinal detachment 1 3.2
Sickle cell retinopathy 1 3.2
Diabetic retinopathy alone 1 3.2
Angle closure glaucoma 1 3.2
Uveitis 1 3.2
Total 31 100.0
*DR: Diabetic retinopathy, CRVO: Central retina vein occlusion, BRVO: Branch 
retina vein occlusion, CRAO: Central retina artery occlusion
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Systemic hypertension and DM, either alone or in 
combination, were the most important systemic 
disorders associated with NVG in this study. Both 
of these disorders may lead to retina ischemia and 
consequent neovascularization of the anterior segment 
of the eyes. Six (19.4%) patients were blind (cause of 
blindness not stated in the charts) in the contralateral 
eye at presentation and this underscores the importance 
of comprehensive eye examination for diabetic and 
hypertensive patients at regular patients. At the very 
least, each patient should have visual acuity and a 
direct fundoscopy at every clinic visit.
Couching was the etiology of NVG in three patients in 
this study as was the case in seven cases in the Ibadan 
study.[7] Couching, as a form of treatment for cataract, 
is still performed in Nigeria despite the availability of 
modern methods of cataract surgery. In the Nigerian 
National Blindness and Visual Impairment Survey, 
46.1% of all operated cataracts was by couching.[14] The 
fi nding of couching as an etiology of NVG in this study 
suggests a persistent gap between availability of and 
accessibility to modern cataract surgery in Nigeria. In 
Lagos alone there are at least two tertiary eye centers, 
six secondary eye centers and numerous private 
ophthalmologists’ clinics and yet patients still choose 
to patronize couching practitioners.
The majority of patients 24 (76.8%) received ocular 
medications alone as a form of treatment. This may be 
due to lack of funds to access other forms of treatment 
which are considerably more expensive. A dose of 
bevacizumab injection and a session of retina laser 
photocoagulation treatment, for example, may cost up to 
35,000:00 naira (about 200 US dollars) each, a sum which 
is about twice the minimum wage in Nigeria. On the other 
hand it may be that patients did not wish to have any 
further treatments once the immediate concerns of pain 
have been alleviated by the initial ocular medications. 
Nonetheless, the result suggests a failure to deliver a 
particular form of eye care service to those who need it.
Most patients in this study presented with IOP of 
30 mmHg or more, indicating a greater possibility of 
optic nerve damage and consequent loss of vision. 
The average IOP reduction of 19 mmHg occurred in 
fi ve patients who came for follow up and received a 
combination therapy of ocular medications (pressure 
lowering and anti-infl ammatory medications), 
intravitreal bevacizumab and pan-retina laser 
photocoagulation. This suggests that a combination 
therapy may reduce IOP and, perhaps, preserve vision 
in NVG if the patient presents early. None of the patients 
in this study received such forms of treatment as valve 
drainage implants or cyclo-destruction by laser or 
cryo-therapy. This represents a limitation of the options 
of treatment for NVG in our center but their impact on 
outcome of treatment in our environment needs to be 
studied as most of the patients presented rather late.
CONCLUSION
Late presentation, loss to follow up and lack of full and 
complete treatment regime were important fi ndings in 
this study. A routine eye examination for patients at risk 
is essential for early detection and prompt treatment 
for be  er visual outcome. Such patients should at least 
include all diabetics and hypertensives.
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